Government-Owned Inventions; Availability for Licensing, 10374-10375 [2011-4171]
Download as PDF
<![CDATA[
10374
Federal Register / Vol. 76, No. 37 / Thursday, February 24, 2011 / Notices
by medical professionals for medical
imaging.
William F. Ryan .............
2,400
Thanks to its swiftly improved
display quality, the smartphone has
Total ...............................
18,980 been advocated by the medical imaging
vendors for viewing medical images in
E-mail comments to
specific conditions that require urgency
paperwork@hrsa.gov or mail the HRSA
of the read or when full-size workstation
Reports Clearance Officer, Room 10–33, displays are not readily available.
Parklawn Building, 5600 Fishers Lane,
However, as a hand-held device, the
Rockville, MD 20857. Written comments viewing conditions of a smartphone (e.g.
should be received within 60 days of
ambient light and hand shaking) are not
this notice.
predictable and may adversely affect the
perceived image quality. The present
Dated: February 17, 2011.
invention proposes the use of the builtReva Harris,
in sensors in iPhone-like mobile devices
Acting Director, Division of Policy and
to detect and adapt to the viewing
Information Coordination.
conditions and hand shaking. The built[FR Doc. 2011–4162 Filed 2–23–11; 8:45 am]
in camera can be used to capture the
BILLING CODE 4165–15–P
ambient light for determining the
adaptation level, which affects the
brightness, contrast and color
DEPARTMENT OF HEALTH AND
perception. The built-in accelerometers
HUMAN SERVICES
can be used to detect orientation and
moving velocity of the display, which
National Institutes of Health
affect the perceived spatial resolution.
Government-Owned Inventions;
The execution of critical tasks can be
Availability for Licensing
then censored based on the detected
scenario. If the viewing conditions are
AGENCY: National Institutes of Health,
not suitable for reading medical images,
Public Health Service, HHS.
for example, then the program could
ACTION: Notice.
halt until the viewing conditions
improve.
SUMMARY: The inventions listed below
This invention can be used by
are owned by an agency of the U.S.
consumer-grade mobile devices which
Government and are available for
were not originally designed for medical
licensing in the U.S. in accordance with purposes to show medical images with
35 U.S.C. 207 to achieve expeditious
improved perceived image quality.
commercialization of results of
Applications
Federally-funded research and
development. Foreign patent
• Biomedical imaging.
applications are filed on selected
• Radiology.
inventions to extend market coverage
Advantages: Improved image quality
for companies and may also be available of mobile devices that minimizes issues
for licensing.
related to inadequate light conditions or
hand movement.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
Development Status
listed below may be obtained by writing
• Algorithm developed.
to the indicated licensing contact at the
• Prototype is being built.
Office of Technology Transfer, National
Inventors: Wei-Chung Cheng and
Institutes of Health, 6011 Executive
Aldo G. Badano (FDA).
Boulevard, Suite 325, Rockville,
Patent Status: HHS Reference No. E–
Maryland 20852–3804; telephone: 301/
284–2010/0—Research Tool/Software.
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will Patent protection is not being pursued
for this technology.
be required to receive copies of the
Licensing Status: Available for
patent applications.
licensing.
LightCensor: A Detecting and Control
Licensing Contacts
Program That Guarantees That a
• Uri Reichman, PhD, MBA; 301–
Mobile Device Be Used Only in
Appropriate Lighting Conditions When 435–4616; UR7a@nih.gov.
• Michael Shmilovich, Esq.; 301–
Displaying Medical Images
435–5019; ShmilovichM@mail.nih.gov.
Description of Invention: The
invention provides algorithm that when A Novel MRI Phantom for Breast
Imaging
used in a mobile device (e.g.
smartphone) can enhance the
Description of Invention: The
capabilities of mobile devices to be used invention offered for licensing is in the
emcdonald on DSK2BSOYB1PROD with NOTICES
Over 3 years
VerDate Mar<15>2010
17:21 Feb 23, 2011
Jkt 223001
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
field of breast cancer imaging. More
specifically it relates to novel breast
phantoms that can be used as reference
in breast imaging. The anthropomorphic
breast phantoms described in the
invention comprise a combination of
adipose tissue mimicking components
and fibroglandular tissue mimicking
components. Typically, x-ray
attenuation coefficients or magnetic
resonance relaxation times T1 and T2
are selected that are sufficiently similar
to actual patient tissues. The mimicking
components are distributed within the
phantom such that images of the
phantom contain features similar to
those of patient tissues. A breast
phantom can be based on a lard/egg
white combination that is shaped to
approximate a human breast, or a
compressed human breast as prepared
for mammography. The phantoms can
include lesion chambers that permit the
introduction of contrast agents to
simulate benign or malignant lesions,
and contrast agent concentration can be
time varied to produce washout curves.
Applications: Imaging of breast cancer
as well as calibration and optimization
of related instrumentation.
Advantages: The breast phantoms of
the invention precisely mimics human
breast in several of their characteristics
as mentioned above. Furthermore, they
can be utilized in conjunction with xray mammography and/or with MRI.
The phantoms may therefore be used to
enhance the accuracy and quality of
diagnostic breast imaging, and thus
avoid unnecessary procedures. In
addition, wide-spread use of the breast
phantoms will lead to improved
standardization in the field of breast
imaging.
Development Status: The methods of
making the phantoms have been
established. Clinical usefulness has to
be established.
Inventors: Melanie Freed and Aldo
Badano (FDA).
Patent Status
• U.S. Provisional Application No.
61/385,929 filed 23 Sep 2010 (HHS
Reference No. E–126–2010/0–US–01),
entitled ‘‘Evaluation of Breast Dynamic
Contrast-enhanced Magnetic Resonance
Imaging’’.
• U.S. Provisional Application No.
61/424,495 filed 17 Dec 2010 (HHS
Reference No. E–126–2010/1–US–01),
entitled ‘‘Anthropomorphic, X-ray and
Dynamic Contrast-Enhanced Magnetic
Resonance Imaging Phantom for
Quantitative Evaluation of Breast
Imaging Techniques’’.
Licensing Status: Available for
licensing.
E:\FR\FM\24FEN1.SGM
24FEN1
Federal Register / Vol. 76, No. 37 / Thursday, February 24, 2011 / Notices
Licensing Contacts
• Uri Reichman, PhD, MBA; 301–
435–4616; UR7a@nih.gov.
• John Stansberry, PhD; 301–435–
5236; Stansbej@mail.nih.gov.
emcdonald on DSK2BSOYB1PROD with NOTICES
Meningococcal and Pneumococcal
Conjugate Vaccine and Method of Using
Same
Description of Invention:
Pneumococcal diseases are a major
public health problem all over the
world. The etiological agent,
Streptococcus pneumoniae (the
pneumococcus) is surrounded by a
polysaccharide capsule. Differences in
the composition of this capsule permit
serological differentiation between
about 90 capsular types, some of which
are frequently associated with
pneumococcal disease, others rarely.
Invasive pneumococcal infections
include pneumonia, meningitis and
febrile bacteremia; among the common
non-invasive manifestations are otitis
media, sinusitis and bronchitis. At least
1 million children die of pneumococcal
disease every year, most of these being
young children in developing countries.
Vaccination is the only available tool to
prevent pneumococcal disease. The
recent development of widespread
microbial resistance to essential
antibiotics underlines the urgent need
for more efficient pneumococcal
vaccines.
Meningococcal disease is a contagious
bacterial disease caused by the
meningococcus (Neisseria meningitidis).
It is spread by person-to-person contact
through respiratory droplets of infected
people. There are 3 main clinical forms
of the disease: the meningeal syndrome,
the septic form and pneumonia. The
onset of symptoms is sudden and death
can follow within hours. In as many as
10–15% of survivors, there are
persistent neurological defects,
including hearing loss, speech
disorders, loss of limbs, mental
retardation and paralysis. Up to 5–10%
of a population may be asymptomatic
carriers. These carriers are crucial to the
spread of the disease as most cases are
acquired through exposure to
asymptomatic carriers. Waning
immunity among the population against
a particular strain favors epidemics, as
do overcrowding and climatic
conditions such as dry seasons or
prolonged drought and dust storms. The
disease mainly affects young children,
but is also common in older children
and young adults. The disease occurs
sporadically throughout the world with
seasonal variations and accounts for a
proportion of endemic bacterial
meningitis. However, the highest
VerDate Mar<15>2010
17:21 Feb 23, 2011
Jkt 223001
burden of the disease is due to the
cyclic epidemics occurring in the
African meningitis belt.
With the burden of S. pneumoniae
and N. meningitidis infection on the
public health system at a global scale, it
is desirable to have a single vaccine that
is effective to prevent disease resulting
from the infection of both pathogens.
This application claims immunogenic
compositions for inducing an immune
response to two different
microorganisms, S. pneumoniae and N.
meningitidis. The application also
claims conjugate vaccines comprising at
least one N. meningitidis capsular
polysaccharide conjugated to a
recombinant pneumococcal protein.
Applications: Conjugate vaccine for
the prevention and/or therapy of
meningococcal and pneumococcal
infections.
Advantages
• Rapid production time.
• Higher-yielding manufacturing
method.
• Low manufacturing cost.
Development Status: Preclinical
studies have been conducted by the
inventors.
Inventors
• Stanley S. Tai (Howard University).
• Che-Hung Robert Lee (FDA).
Patent Status: HHS Reference No. E–
030–2010/0—
• U.S. Patent Application No. 12/
425,232 filed 16 Apr 2009.
• PCT/US2010/031083 filed 14 Apr
2010.
Licensing Status: Available for
licensing.
Licensing Contact: Daniel G. McCabe;
Associate General Counsel for Business
Transactions; Howard University, Office
of the General Counsel; 2400 6th Street,
NW., Suite 321; Washington, DC 20059;
Office: (202) 806–2650; Fax: (202) 806–
6357; E-mail: dmccabe@howard.edu.
Dated: February 16, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–4171 Filed 2–23–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
ACTION:
10375
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Terahertz Spatial Light Modulator
System for Adaptive Near-Field
Imaging
Description of Technology: The
invention offered for licensing is in the
field of imaging microscopes and relates
to a terahertz light modulator system,
and in particular to a terahertz spatial
light modulator system for adaptive
near-field imaging.
More specifically, the invention
relates to a spatial light modulator
system for adaptive near-field imaging
having an optical source for transmitting
an optical beam through a filter which
is controlled to convert the optical light
beam into a filtered optical light beam
to define one or more transmission
pathways through a photoconductive
material. The system further includes a
terahertz light source for transmitting a
terahertz beam through one or more
transmission pathways defined by the
filtered optical light beam through the
photoconductive material for
illuminating and scanning the sample
without the use of moving structural
components. The device would allow
micron-scale spatial resolution, would
remove the need to mechanically scan a
sample, and would allow automatic
adjustment of image resolution and
transmitted terahertz power. The nearfield terahertz microscope of the
invention could have a compact, fibercoupled sensor head with no moving
parts—ideal for scientific, medical, and
industrial applications like crystal
growth optimization, skin cancer
diagnosis, and semiconductor chip
inspection. In one application, such as
‘‘one-cut’’ surgery, the compact sensor
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 76, Number 37 (Thursday, February 24, 2011)]
[Notices]
[Pages 10374-10375]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-4171]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
LightCensor: A Detecting and Control Program That Guarantees That a
Mobile Device Be Used Only in Appropriate Lighting Conditions When
Displaying Medical Images
Description of Invention: The invention provides algorithm that
when used in a mobile device (e.g. smartphone) can enhance the
capabilities of mobile devices to be used by medical professionals for
medical imaging.
Thanks to its swiftly improved display quality, the smartphone has
been advocated by the medical imaging vendors for viewing medical
images in specific conditions that require urgency of the read or when
full-size workstation displays are not readily available. However, as a
hand-held device, the viewing conditions of a smartphone (e.g. ambient
light and hand shaking) are not predictable and may adversely affect
the perceived image quality. The present invention proposes the use of
the built-in sensors in iPhone-like mobile devices to detect and adapt
to the viewing conditions and hand shaking. The built-in camera can be
used to capture the ambient light for determining the adaptation level,
which affects the brightness, contrast and color perception. The built-
in accelerometers can be used to detect orientation and moving velocity
of the display, which affect the perceived spatial resolution. The
execution of critical tasks can be then censored based on the detected
scenario. If the viewing conditions are not suitable for reading
medical images, for example, then the program could halt until the
viewing conditions improve.
This invention can be used by consumer-grade mobile devices which
were not originally designed for medical purposes to show medical
images with improved perceived image quality.
Applications
Biomedical imaging.
Radiology.
Advantages: Improved image quality of mobile devices that minimizes
issues related to inadequate light conditions or hand movement.
Development Status
Algorithm developed.
Prototype is being built.
Inventors: Wei-Chung Cheng and Aldo G. Badano (FDA).
Patent Status: HHS Reference No. E-284-2010/0--Research Tool/
Software. Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Licensing Contacts
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
Michael Shmilovich, Esq.; 301-435-5019;
ShmilovichM@mail.nih.gov.
A Novel MRI Phantom for Breast Imaging
Description of Invention: The invention offered for licensing is in
the field of breast cancer imaging. More specifically it relates to
novel breast phantoms that can be used as reference in breast imaging.
The anthropomorphic breast phantoms described in the invention comprise
a combination of adipose tissue mimicking components and fibroglandular
tissue mimicking components. Typically, x-ray attenuation coefficients
or magnetic resonance relaxation times T1 and T2 are selected that are
sufficiently similar to actual patient tissues. The mimicking
components are distributed within the phantom such that images of the
phantom contain features similar to those of patient tissues. A breast
phantom can be based on a lard/egg white combination that is shaped to
approximate a human breast, or a compressed human breast as prepared
for mammography. The phantoms can include lesion chambers that permit
the introduction of contrast agents to simulate benign or malignant
lesions, and contrast agent concentration can be time varied to produce
washout curves.
Applications: Imaging of breast cancer as well as calibration and
optimization of related instrumentation.
Advantages: The breast phantoms of the invention precisely mimics
human breast in several of their characteristics as mentioned above.
Furthermore, they can be utilized in conjunction with x-ray mammography
and/or with MRI. The phantoms may therefore be used to enhance the
accuracy and quality of diagnostic breast imaging, and thus avoid
unnecessary procedures. In addition, wide-spread use of the breast
phantoms will lead to improved standardization in the field of breast
imaging.
Development Status: The methods of making the phantoms have been
established. Clinical usefulness has to be established.
Inventors: Melanie Freed and Aldo Badano (FDA).
Patent Status
U.S. Provisional Application No. 61/385,929 filed 23 Sep
2010 (HHS Reference No. E-126-2010/0-US-01), entitled ``Evaluation of
Breast Dynamic Contrast-enhanced Magnetic Resonance Imaging''.
U.S. Provisional Application No. 61/424,495 filed 17 Dec
2010 (HHS Reference No. E-126-2010/1-US-01), entitled
``Anthropomorphic, X-ray and Dynamic Contrast-Enhanced Magnetic
Resonance Imaging Phantom for Quantitative Evaluation of Breast Imaging
Techniques''.
Licensing Status: Available for licensing.
[[Page 10375]]
Licensing Contacts
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
John Stansberry, PhD; 301-435-5236; Stansbej@mail.nih.gov.
Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using
Same
Description of Invention: Pneumococcal diseases are a major public
health problem all over the world. The etiological agent, Streptococcus
pneumoniae (the pneumococcus) is surrounded by a polysaccharide
capsule. Differences in the composition of this capsule permit
serological differentiation between about 90 capsular types, some of
which are frequently associated with pneumococcal disease, others
rarely. Invasive pneumococcal infections include pneumonia, meningitis
and febrile bacteremia; among the common non-invasive manifestations
are otitis media, sinusitis and bronchitis. At least 1 million children
die of pneumococcal disease every year, most of these being young
children in developing countries. Vaccination is the only available
tool to prevent pneumococcal disease. The recent development of
widespread microbial resistance to essential antibiotics underlines the
urgent need for more efficient pneumococcal vaccines.
Meningococcal disease is a contagious bacterial disease caused by
the meningococcus (Neisseria meningitidis). It is spread by person-to-
person contact through respiratory droplets of infected people. There
are 3 main clinical forms of the disease: the meningeal syndrome, the
septic form and pneumonia. The onset of symptoms is sudden and death
can follow within hours. In as many as 10-15% of survivors, there are
persistent neurological defects, including hearing loss, speech
disorders, loss of limbs, mental retardation and paralysis. Up to 5-10%
of a population may be asymptomatic carriers. These carriers are
crucial to the spread of the disease as most cases are acquired through
exposure to asymptomatic carriers. Waning immunity among the population
against a particular strain favors epidemics, as do overcrowding and
climatic conditions such as dry seasons or prolonged drought and dust
storms. The disease mainly affects young children, but is also common
in older children and young adults. The disease occurs sporadically
throughout the world with seasonal variations and accounts for a
proportion of endemic bacterial meningitis. However, the highest burden
of the disease is due to the cyclic epidemics occurring in the African
meningitis belt.
With the burden of S. pneumoniae and N. meningitidis infection on
the public health system at a global scale, it is desirable to have a
single vaccine that is effective to prevent disease resulting from the
infection of both pathogens. This application claims immunogenic
compositions for inducing an immune response to two different
microorganisms, S. pneumoniae and N. meningitidis. The application also
claims conjugate vaccines comprising at least one N. meningitidis
capsular polysaccharide conjugated to a recombinant pneumococcal
protein.
Applications: Conjugate vaccine for the prevention and/or therapy
of meningococcal and pneumococcal infections.
Advantages
Rapid production time.
Higher-yielding manufacturing method.
Low manufacturing cost.
Development Status: Preclinical studies have been conducted by the
inventors.
Inventors
Stanley S. Tai (Howard University).
Che-Hung Robert Lee (FDA).
Patent Status: HHS Reference No. E-030-2010/0--
U.S. Patent Application No. 12/425,232 filed 16 Apr 2009.
PCT/US2010/031083 filed 14 Apr 2010.
Licensing Status: Available for licensing.
Licensing Contact: Daniel G. McCabe; Associate General Counsel for
Business Transactions; Howard University, Office of the General
Counsel; 2400 6th Street, NW., Suite 321; Washington, DC 20059; Office:
(202) 806-2650; Fax: (202) 806-6357; E-mail: dmccabe@howard.edu.
Dated: February 16, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-4171 Filed 2-23-11; 8:45 am]
BILLING CODE 4140-01-P
